TY - JOUR
T1 - Drug-Induced Liver Disease
T2 - Clinical Course
AU - Saithanyamurthi, Hemamala
AU - Faust, Alison Jazwinski
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Drug-induced liver injury (DILI) is a term used to describe a spectrum of clinical presentations and severity that ranges from mild elevation of liver enzymes on routine blood work to acute liver failure and death. Approximately 10% of all patients with DILI develop acute liver failure resulting in death or liver transplantation. DILI may be prolonged with persistence of elevated liver enzymes for longer than 6 months in approximately 5% to 20% of cases. Cirrhosis and long-term liver-related morbidity and mortality have also been described but are rare, occurring in 1% to 3% of cases.
AB - Drug-induced liver injury (DILI) is a term used to describe a spectrum of clinical presentations and severity that ranges from mild elevation of liver enzymes on routine blood work to acute liver failure and death. Approximately 10% of all patients with DILI develop acute liver failure resulting in death or liver transplantation. DILI may be prolonged with persistence of elevated liver enzymes for longer than 6 months in approximately 5% to 20% of cases. Cirrhosis and long-term liver-related morbidity and mortality have also been described but are rare, occurring in 1% to 3% of cases.
UR - http://www.scopus.com/inward/record.url?scp=84995948172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995948172&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2016.08.007
DO - 10.1016/j.cld.2016.08.007
M3 - Review article
C2 - 27842773
AN - SCOPUS:84995948172
SN - 1089-3261
VL - 21
SP - 21
EP - 34
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
IS - 1
ER -